Compound Crackdown: The FDA Tightens up on Restrictions for Compounded Drug Ingredients and Advertisements In response to known risks about misuse, and unverified claims about quality, efficacy, and safety, the FDA is taking actions to impose more restrictions regarding non-approved and mass-marketed compounded medications, including certain GLP-1 products. The administration will address both usage of active ingredients in GLP-1s and the misleading advertising and marketing surrounding these drugs. June 23, 2026 Member Benefits, Practice Management, RCMA/CMA, Resources, Risk Management ProAssurance, RCMA, Resources, Risk Management 0 0 Comment Read More »